For fifteen years, it was whether GLP-1 receptor activation could protect neurons, and the preclinical answer was a repeated yes
Lack of access to GLP-1 drugs to those that cannot afford it could widen health disparities among the wealthy and the poor
Chadebech P, Michel M, Janvier D, Yamada K, Copie-Bergman C, Bodivit G, et al
Given the biomarker findings, its still possible that a GLP-1 medication can slow the progression of Alzheimers, just not this particular one or in this particular way
PLOS ONE, 15(9), e0239252
For air travel, peptides and syringes should go in carry-on luggage with documentation of the prescription